All Episodes
WTR Healthcare Happenings — 51 episodes
ExoZymes (EXOZ): Unlocking Hard-to-Scale Molecules with AI-Driven, Cell-Free Biomanufacturing
Hidden Gems - Unlocking Value in Biotech's Most Overlooked Stocks
Vivos Therapeutics (VVOS): 2025 Results and Path to Cash Flow Breakeven by End-2026
Trump's Psychedelic Medicine Executive Order: What It Means for Patients and Investors
WTR Insights Conference Preview: Nurexone's Nerve Regeneration & Anixa's Cancer Immunotherapy in Focus
Circular Genomics: Cracking the Brain Code with Circular RNA
Unmasking the Treatment Landscape for Obstructive Sleep Apnea (OSA)
Psychedelics at a Turning Point: The Trials That Could Change Mental Health Treatment
Anixa Biosciences (ANIX): CEO Dr. Amit Kumar on Why 2026 Is Poised to Be a Defining Year
Omniscient Neurotechnology: Scaling up Clinical Connectomics SaaS Strategy and Neurotech Vision
Decoy Therapeutics (DCOY): CEO Rick Pierce on the Company’s Groundbreaking Approach to Drug Development in the AI/ML Era
Medicus Pharma (MDCX): De‑Risking Drug Development to Capture a High‑Growth Market Opportunity
NurExone Biologic (OTCQB: NRXBF / TSXV: NRX): CEO Dr. Lior Shaltiel on How the Company Stands Out as an Early‑Clinical‑Stage Biotech
Taking Aim at Norovirus; Cocrystal Pharma's (COCP) Clinical Antiviral Opportunity
How Entropy Neurodynamics (ASX: ENP) Is Shaping Psychedelic‑Assisted Therapy: Psilocin Programs, Binge Eating Disorder, and EEG Biomarker
Anixa' (ANIX) T-Cell Innovations Demonstrate Early Breakthrough Potential in Solid Tumors
The lure of the NASDAQ for Biotechs
Redefining Cancer Treatment: Calidi Biotherapeutics’ Approach to Enable Systemic Oncolytic Virotherapy for Metastatic Disease
Co-Diagnostic' Technology to Deliver Accessible, High-Fidelity Gold Standard PCR Testing Like No Other
CEO Jagi Gill on How Apyron' Innovative Neurostimulation Solution Breaks the Chronic Pain Barrier
RenovoRx’ Differentiated Targeted Drug Delivery Platform Addressing Hypovascular cancers
Vivos Therapeutics’ Mission to Transform Sleep Treatment
GenSight Biologics' Novel Gene Therapy Approach to Reversing Blindness from Genetic Eye Disorders
Ainos' Director of Corporate Development Jack Lu Discusses the AI Nose Platform' continuing 2025 momentum and Looks Ahead into 2026
The Psychedelic Investment Environment: A New Era of Optimism
Solvonis Therapeutics: Redefining Treatment for Alcohol Use Disorder Through Capital-Efficient Innovation
Reversing the Irreversible: NurExone Biologic’s (NRXBF) Regenerative Exosome Therapy for Spinal Cord and Nerve Injuries
PharmAla Biotech’s CEO Nick Kadysh On Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL
CEO Dr. Amit Kumar Discusses Anixa Biosciences' Innovative Approach to Help T-Cells Address Solid Tumors
Veru's CEO Mitch Steiner on Enobosarm's value-added to the booming GLP-1 Weight Loss Drug Market
Revolutionizing Stroke Prevention: InspireMD’s CGuard® Prime and the Future of Carotid Stenting
Transforming Global Healthcare Access: Doc.com’s Mission for Free Basic Telemedicine
Psychedelics Sector Deals 2025: AbbVie/Gilgamesh Impact and Market Outlook
Ludwig's Dr. Marvin Hausman on Why Its Cheek-Swabbing mRNA Technology Platform Promises to be a Revolutionary Diagnostic Tool
CEO Brent Lucas on Why Envoy Medical's Device Technology is Currently the Only Change Agent in Hearing Health
Ainos' Director of Corporate Development Jack Lu on Why SmellTech Platform AI Nose is a Foundational Product in AI
Lisata Therapeutics' CEO Dr. David Mazzo and CMO Dr. Kristen Buck On the Promise Of Certepetide for Pancreatic Cancer
Cybin CEO Doug Drysdale On What Distinguishes CYB003 from Other Aspiring Novel Depression Treatments
A Conversation with PharmAla Biotech CEO Nick Kadysh on What the Trump FDA and AI mean for the Biotech Landscape
Trevi Therapeutics CEO Jennifer Good Discusses Oral Haduvio Benefit in Chronic Cough
How the Biomarker Era Will Transform the CNS Treatment Landscape with Psilera CEO Dr. Chris Witowski
Apimeds Pharmaceuticals CEO Erik Emerson Discusses Purified Bee Venom for Knee Osteoarthritis and Other Inflammatory Conditions
Zomedica's (OTCQB: ZOMDF) CEO Highlights Its Innovative Product Offerings and Significant Growth Opportunities in the Animal Healthcare Market
Enlivex Therapeutics CEO Oren Hershkovitz, PhD Discusses Allocetra Cell Therapy and Recent Knee Osteoarthritis Data
Most-Favored-Nation Drug Pricing Lacks Executive Plan
Current State of Biotech, Market Pressure Points, Obesity and PD-1/VEGF
WTR Biotech Flashcast: Neuroscience, Alzheimer’s and Biogen IOC
Annovis Bio's CEO Discusses the promise of Buntanetap in Redefining the Treatment of Alzheimer's and Parkinson's and Next Steps
Veru, Inc. CEO Mitch Steiner Discusses Recent Enobosarm Data and Preserving Muscle While on GLP-1 Obesity Drugs
OS Therapies CEO Paul Romness and CBO Gerald Commisiong Discuss Recent OST-HER2 Phase 2b Data and Next Steps
Launch of WTR Biotech Spotlight Podcast with Tim Gerdeman and Do Kim